For its fourth fiscal quarter (ending December 31), Myriad Genetics Inc (NASDAQ: MYGN) has reported a 31% increase in E.P.S. from $-0.36 a year ago to $-0.47 in the current quarter. For the latest four quarters through December 31, E.P.S. were $-1.41 compared to $-3.18 a year ago — a decline of -56%.
Recent Price Action
Myriad Genetics Inc (NASDAQ: MYGN) stock closed at $13.78 on 2/24/25 after a decline of -2.8%. Moreover, trading volume in this decline was above average at 128% of normal. The stock has declined -5.9% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Myriad Genetics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Myriad Genetics has a poor Appreciation Score of 24 and a very low Power Rating of 9, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment